{"entity":{"id":"nct07387471","kind":"trial","name":"Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobu","aka":[],"tldr":"A phase 2 trial of Venetoclax in waldenström macroglobulinaemia, run by AbbVie, active and no longer recruiting.","summary":"Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) is a phase 2 interventional study registered as NCT07387471 by AbbVie, with 14 participants planned, started 2026-03-17 and due to reach its primary completion in 2028-07. Interventions recorded: Venetoclax. Conditions listed: Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07387471","url":"https://clinicaltrials.gov/study/NCT07387471"}],"tags":["ctgov-ingest"],"related":[],"cancers":["waldenstrom"],"sections":[],"technologies":[],"targets":[],"drugs":["venetoclax"],"companies":["abbvie"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07387471","phase":"2","setting":"A Phase 2 Study of Venetoclax Monotherapy in Japanese Subjects With Relapsed or Refractory Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma","sponsor":"AbbVie","enrolled":14,"outcomes":[]},"route":"/trials/nct07387471/","neighbours":{"cancer":[{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/"}],"drug":[{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"}]}}